结直肠癌

Professor of Surgery

Georgetown University School of Medicine

Georgetown

DC

Regional Chief of Surgery

MedStar Health

Baltimore

MD

利益声明

DES declares that he has no competing interests.

Associate Program Director

Department of Surgery

MedStar Franklin Square Medical Center

Baltimore

MD

利益声明

DML declares that he has no competing interests.

Division Director, Medical Oncology

Sinai and Northwest Hospital

LifeBridge Health

Alvin & Lois Lapidus Cancer Institute

Baltimore

MD

利益声明

PPK declares that she has no competing interests.

Assistant Professor

Department of Radiation Oncology

University of Maryland Upper Chesapeake Medical Center KCC Radiation Oncology

Bel Air

MD

利益声明

KANC declares that she has no competing interests.

Dr David E. Stein, Dr David M Lisle, Dr Pallavi P Kumar, and Dr Kamila A Nowak-Choi would like to gratefully acknowledge Dr Juan L. Poggio, Dr Jascha Rubin, Dr Najjia Mahmoud, Dr Emily Carter Paulson, Dr Gary Atkin, Dr Anne Ballinger, Dr Mark O'Hara, Dr Mark Harrison, and Dr Robert Glynne-Jones, previous contributors to this topic.

利益声明

JLP, JR, NM, ECP, MOH, GA, and AB declare that they have no competing interests. MH is the chair of the Mount Vernon Upper GI Tumour Site Specific Group and a member of the National Cancer Research Institute anal, rectal, and advanced colorectal groups. He has also received honoraria for speaking and has been supported to attend international meetings on gastrointestinal cancer from Roche. He has also received research funding from Pfizer for a trial in rectal cancer. RGJ is the chief medical adviser to the charity Bowel Cancer UK. He has received honoraria for lectures from Roche, Sanofi, and Pfizer. He has received funding for the EXTRA study, involving capecitabine and radiotherapy in anal cancer, published in the International Journal of Radiation Biology Physics. RGJ has also received funding and free cetuximab for an ongoing phase 1/2 study integrating cetuximab into chemoradiation in rectal cancer, and has an agreement from Roche to supply bevacizumab for 3 months to 60 patients in one randomised phase 2 study as neoadjuvant chemotherapy in rectal cancer (BACCHUS). He has also been supported by Roche to attend international meetings in gastrointestinal cancer.

Consultant Colorectal Surgeon

St Mark's Hospital and Academic Institute

Northwick Park

Middlesex

UK

利益声明

SC declares that she has no competing interests.

Chief of Staff

Chairman

Department of Colorectal Surgery

Cleveland Clinic

Weston

FL

利益声明

SW declares that he has no competing interests.